Allergan Gets Competing Merger Offer To Ackman’s Pershing Square, Valeant

Allergan, Inc. (NYSE:AGN) has been in the news often throughout the year so far.  Beginning on April 22, 2014, Valeant Pharmaceuticals Intl Inc (NYSEVRX) (TSE:VRX) approached the board of Allergan with the interest of acquiring the botox maker, which was valued around $152.88 per share.  Early May 2014, Allergan decided against the proposal and voted against the acquisition.  Only a few weeks later, around May 28^th, Pershing Square Capital manager, Bill Ackman, got onboard and eyed a joint acquisition with Valeant of Allergan.  However, as several months went by, no new progress was being made by Ackman and Valeant.  In an effort to insight more enthusiasm, Valeant directors sent a letter to Allergan’s directors with the proposal...